Efficacy and safety of neoadjuvant immunotherapy combined with chemotherapy in locally advanced esophageal cancer: A meta-analysis
Open Access
- 5 September 2022
- journal article
- research article
- Published by Frontiers Media SA in Frontiers in Oncology
- Vol. 12, 974684
Abstract
Objective: The progress of neoadjuvant therapy for resectable locally advanced esophageal cancer has been stagnant. There has been much progress in immunotherapy for advanced esophageal cancer, but the efficacy and safety of neoadjuvant immunotherapy for resectable locally advanced esophageal cancer have not yet been definitively demonstrated.Methods: Original articles describing the safety and efficacy of neoadjuvant immunotherapy in resectable locally advanced esophagus published until July 2022 were retrieved from PubMed, Embase, and the Cochrane Library. The ratio (OR) and 95% confidence interval (CI) were calculated to conduct heterogeneity and subgroup analysis.Results: In total, 759 patients from 21 studies were enrolled. The effectiveness of neoadjuvant immunotherapy in combination with chemotherapy was evaluated using the major pathologic response (MPR) and pathologic complete response (PCR). In the enrolled patients, 677 were treated surgically and 664 achieved R0 resection. Major pathological remission was achieved in 52.0% (95% CI: 0.44–0.57) of patients on neoadjuvant immunotherapy combined with chemotherapy and complete pathological remission in 29.5% (95% CI: 0.25–0.32) of patients. The safety was primarily assessed by the incidence of treatment-related adverse events (TRAEs) and surgical resection rates. The incidence of TRAEs and the surgical resection rate combined ORs were 0.15 (95% CI: 0.09–0.22) and 0.86 (95% CI: 0.83–0.89), respectively.Conclusion: Neoadjuvant immunotherapy combined with chemotherapy in locally advanced resectable esophageal cancer is effective and safe.Keywords
Funding Information
- Education Department of Jilin Province
- Department of Science and Technology of Jilin Province
This publication has 47 references indexed in Scilit:
- The epidemic of oesophageal carcinoma: Where are we now?Cancer Epidemiology, 2016
- The Interplay of Immunotherapy and Chemotherapy: Harnessing Potential SynergiesCancer Immunology Research, 2015
- Surgery Alone Versus Chemoradiotherapy Followed by Surgery for Stage I and II Esophageal Cancer: Final Analysis of Randomized Controlled Phase III Trial FFCD 9901Journal of Clinical Oncology, 2014
- Preoperative Chemoradiotherapy for Esophageal or Junctional CancerNew England Journal of Medicine, 2012
- Nodal Metastasis From Locally Advanced Esophageal Cancer: How Neoadjuvant Therapy Modifies Their Frequency and DistributionAnnals of Surgical Oncology, 2011
- Long-Term Results of a Randomized Trial of Surgery With or Without Preoperative Chemotherapy in Esophageal CancerJournal of Clinical Oncology, 2009
- Effects of neoadjuvant radiochemotherapy on pathological staging and prognosis for locally advanced esophageal squamous cell carcinomaDiseases of the Esophagus, 2009
- Improvement in Treatment Results and Long-Term Survival of Patients With Esophageal CancerAnnals of Surgery, 2003
- Toxicity of platinum compoundsExpert Opinion on Pharmacotherapy, 2003
- Surgical resection with or without preoperative chemotherapy in oesophageal cancer: a randomised controlled trialThe Lancet, 2002